Mylan and a group of pharmacy benefit managers have lost a bid to dismiss a class action claiming the drugmaker paid kickbacks to the PBMs in order to drive up the price of its anti-allergy injection EpiPen, a federal judge has ruled.
US District Judge Eric Tostrud in Minnesota ruled Friday, January 15, that the plaintiffs, a group of drug distributors, had successfully pleaded their case that Mylan, Optum, CVS Caremark, and Express Scripts engaged in a conspiracy under the Racketeer Influenced and Corrupt Organizations Act, and that Mylan violated the Sherman Act.
The suit filed in Trenton, New Jersey, Sanofi claimed that Mylan caused it to lose hundreds of millions of dollars in sales by erecting barriers to US consumers’ access to and use of a rival product, Auvi-Q.
In particular, Sanofi claimed that Mylan offered rebates to insurers, pharmaceutical benefit managers and state Medicaid agencies conditioned on Auvi-Q not being an epinephrine auto-injector device they would reimburse for use by consumers.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
DOJ and FTC Introduce Website for Reporting Anti-Competitive Healthcare Practices
Apr 18, 2024 by
CPI
US Congress Advances Legislation to Compel TikTok Sale
Apr 18, 2024 by
CPI
UK Financial Sector Advocates Enhanced Regulatory Accountability
Apr 18, 2024 by
CPI
Google and All 50 States Defend $700 Million Consumer Settlement
Apr 18, 2024 by
CPI
Colorado Enacts First Law to Protect Consumer Brainwave Data
Apr 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI